Among 18 people with Graves' disease taking beta-blockers for rapid heartbeat, batoclimab injections led to a noticeable drop in heart rate within three weeks, and nearly half were able to lower or stop their heart rate medication by nine weeks.
Claim Context
In 18 patients with Graves' disease receiving beta-blockers, batoclimab treatment was associated with a 7 bpm reduction in resting heart rate by week 3 and allowed 8 of 18 patients to reduce or discontinue beta-blockers by week 9.
“Heart rate decreased by 7 bpm by Week 3 (nominal p=0.004), and 8/18 patients receiving beta blockers at baseline were able to reduce or discontinue beta blockers by Week 9.”
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Whether batoclimab consistently reduces resting heart rate and enables beta-blocker discontinuation across randomized trials in Graves' disease.
A systematic review and meta-analysis of all randomized, double-blind, placebo-controlled trials of batoclimab in Graves' disease, including at least 400 participants, with primary outcomes being resting heart rate reduction ≥5 bpm and beta-blocker discontinuation rate at 12 weeks.
Whether batoclimab causes greater reduction in resting heart rate and higher rate of beta-blocker discontinuation compared to placebo in Graves' disease.
A double-blind, placebo-controlled, multicenter trial of 150 adults with Graves' disease and resting heart rate >90 bpm on beta-blockers, randomized 1:1 to batoclimab (680 mg then 340 mg weekly) or placebo for 12 weeks, with primary endpoints being resting heart rate reduction ≥5 bpm and beta-blocker discontinuation at week 9.
Whether heart rate normalization and beta-blocker discontinuation after batoclimab are sustained over 1–2 years.
A prospective cohort study of 250 patients with Graves' disease on beta-blockers treated with batoclimab, measuring resting heart rate and beta-blocker use at baseline, 3, 6, 12, and 24 months.
Whether baseline heart rate or FT3 levels predict likelihood of beta-blocker discontinuation after batoclimab.
A case-control study comparing 50 patients who discontinued beta-blockers after batoclimab to 50 who did not, assessing baseline heart rate, FT3, and ATD dose as predictors.
The proportion of patients on beta-blockers who have discontinued them while receiving batoclimab in clinical practice.
A cross-sectional survey of 300 patients with Graves' disease currently on batoclimab, measuring current beta-blocker use and resting heart rate at a single time point.